Excellent news for Contipharma!
The next-generation LAMPOX™ test developed by Contipharma in Wallonia has obtained marketing authorisation in the Democratic Republic of the Congo (DRC), the epicentre of the Mpox (monkeypox) outbreak in Africa!
This authorisation follows a validation in September by the INRB in Kinshasa, a validation stating that, according to Professor Jean-Jacques Muyembe, Director General of the INRB, “Contipharma’s LAMPOX test, combining speed with good sensitivity and specificity, is extremely useful for detecting the MPOX virus, particularly in epidemic emergency contexts.”
This is the first Mpox diagnostic test to receive this approval in the DRC, validated by the National Institute of Biomedical Research (INRB) in Kinshasa.
What makes LAMPOX™ so innovative
- Speed: Results in under 20 minutes
- Accuracy: Sensitivity and specificity comparable to a traditional PCR test
- Flexibility: Can be used in the field without requiring laboratory processing
This revolutionary technology is a major step forward in the fight against the Mpox outbreak, with future applications for other epidemic situations.
